Medios-ai

Medios-ai has been studied in 2 papers since 2025: 2 observational studies in people; 2 in the past year. The newest paper, Jun 24, 2026: “Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy”.

Exposure

2 papers study it5 findingsUpdated

See all 2 papers on medios-ai

At a glance

The findings reach people, from one lab or study. 2 independent labs in 1 country.

“For glaucoma (n = 109), sensitivity was 98.2% (95% CI: 94-100), specificity 99.0% (95% CI: 97-100), AUROC 0.99.”
Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracyEuropean journal of ophthalmology2026doi:10.1177/11206721261462321

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 1 country
  • Humans2

What did studies of medios-ai find?

1

Studies of medios-ai measured one outcome, Misclassification of leukemic retinopathy as diabetic retinopathy.

Misclassification of leukemic retinopathy as diabetic retinopathy

upin humans1

1 study
  1. Medios-ai is linked with misclassification of leukemic retinopathy as diabetic retinopathy in humans (patients with leukemic retinopathy) (eight patients incorrectly flagged).

    “eight patients with leukemic retinopathy were incorrectly flagged as having DR, revealing a lack of specificity in distinguishing vascular retinal pathologies.”

    Humanspatients with leukemic retinopathyretinan = 8

    AI in the Shadows: Unveiling the Strengths and Blind Spots of Medios AI Retinal Screening in Cancer Care

    Cureus

What is medios-ai linked with?

4

Studies link medios-ai with 4 measures, among them diabetic retinopathy, age-related macular degeneration and glaucoma.

Diabetic retinopathy

upin humans1

1 study
  1. Medios-ai predicts diabetic retinopathy in humans (DR screening) (AUROC 0.92, sensitivity 84.6%, specificity 99.0%).

    “For DR (n = 78), sensitivity was 84.6% (95% CI: 75-92), specificity 99.0% (95% CI: 97-100), AUROC 0.92.”

    Human trialDR screeningn = 78

    Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy

    European journal of ophthalmology

More on Diabetic retinopathy

Age-related macular degeneration

upin humans1

1 study
  1. Medios-ai predicts age-related macular degeneration in humans (AMD screening) (AUROC 0.93, sensitivity 88.9%, specificity 97.5%).

    “For AMD (n = 56), sensitivity was 88.9% (95% CI: 77-96), specificity 97.5% (95% CI: 95-99), AUROC 0.93.”

    Human trialAMD screeningn = 56

    Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy

    European journal of ophthalmology

More on Age-related macular degeneration

Glaucoma

upin humans1

1 study
  1. Medios-ai predicts glaucoma in humans (glaucoma screening) (AUROC 0.99, sensitivity 98.2%, specificity 99.0%).

    “For glaucoma (n = 109), sensitivity was 98.2% (95% CI: 94-100), specificity 99.0% (95% CI: 97-100), AUROC 0.99.”

    Human trialglaucoma screeningn = 109

    Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy

    European journal of ophthalmology

More on Glaucoma

Detection of common retinal diseases

upin humans1

1 study
  1. Medios-ai predicts detection of common retinal diseases in humans (oncology patients; comparison with clinical examination) (Glaucomatous cupping in three patients, DR in two cases, and signs of ARMD in two patients).

    “The AI system accurately identified glaucomatous cupping in three patients, flagged two cases of DR, and detected signs of ARMD in two patients-all consistent with clinical examination.”

    Humansoncology patients; comparison with clinical examinationretinan = 98

    AI in the Shadows: Unveiling the Strengths and Blind Spots of Medios AI Retinal Screening in Cancer Care

    Cureus

More on Detection of common retinal diseases

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months